HYP-2090-PTSA

N/A

Report date: 2025/10/24 15:30:03
NME

Base Information

Drug NameHYP-2090-PTSA
Drug Alias NameHYP-2090PTSAHYP-2090-PTSAHY-0002a
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitorsPhosphatidylinositol 3-kinase modulators
TargetsKRAS G12CPhosphatidylinositol 3-kinase
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEuropeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Huiyu Seacross Pharma Technology Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSichuan Huiyu Seacross Pharma Technology LtdSichuan Huiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A